摘要
目的:研究血清ADAM-17(ADAM metallopeptidase domain 17)、趋化因子FKN(fractalkine)和肿瘤坏死因子α(tumor necrosis factorα,TNF-α)在慢性阻塞性肺疾病(COPD)急性加重期(acute exacerbated chronic obstructive pulmonary disease,AECOPD)患者治疗前后的变化和意义。方法:采用酶联免疫吸附双抗体夹心法(enzyme-linked immunosorbent assay,ELISA),分别检测36例COPD急性加重期患者治疗前后和25例健康体检者(对照组)血清ADAM-17、可溶性趋化因子FKN(sFKN)和TNF-α的含量。结果:COPD急性加重期患者治疗前血清ADAM-17、sFKN和TNF-α浓度均高于治疗后以及对照组,差异有统计学意义(P均<0.01);COPD急性加重期患者治疗前组血清中ADAM-17、sFKN的浓度与TNF-α浓度呈直线正相关性(r=0.889、0.876,P<0.01);治疗后血清中ADAM-17、sFKN的浓度与TNF-α浓度无相关性(r=0.044、0.036,P>0.05)。结论:ADAM-17与趋化因子FKN可能参与了COPD急性加重期气道炎性反应过程。
Objective To explore the role of ADAM - 17, fractalkine and TNF -α in patients with COPD. Method To detect the levels of ADAM -17 ,sFKN and TNF-α in blood serum of 25 cases with healthy （control group） and in before treatment and post -treatment plasma of 36 cases with COPD group with ELLSA. Results The level of ADAM -17 ,sFKN and TNF- α in before treatment group was all significantly higher than those of post -treatment group and control group （P 〈 0. 01 ）. Before treatment, there was significant positive corre- lation between ADAM - 17, sFKN and TNF - ct （ r = 0. 889,0. 876, P 〈 0. 01 ） ; Post - treatment, there was no correlation between ADAM - 17, sFKN and TNF -α（ r = 0. 044,0. 036 ,P 〉 0.05 ）. Conclusion ADAM - 17 and FKN may participate in the progress of airway inflam- mation in COPD.
出处
《吉林医学》
CAS
2012年第4期700-702,共3页
Jilin Medical Journal
基金
遵义医学院附属医院硕士启动基金(基金编号2007056)
